Mga Batayang Estadistika
| LEI | 549300L9VD6FZWFBND47 |
| CIK | 1722926 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to ASLAN Pharmaceuticals Limited - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| November 14, 2024 |
K2 HealthVentures Equity Trust LLC - SC 13G/A SC 13G/A 1 ef20038299sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Aslan Pharmaceuticals Limited (Name of Issuer) Ordinary Shares, par value $0.01 per share (Title of Class of Securities) 04522R200** (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this S |
|
| November 14, 2024 |
Lind Global Fund II LP - JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Ordinary Shares, par value $0.01 per share, of ASLAN Pharmaceuticals Limited shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G. November 14, 2024 LIND GLOBAL FUND II LP By: Lind Global Part |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ASLAN Pharmaceuticals Limited (Name of Issuer) Ordinary Shares, par value $0.01 per share (Title of Class of Securities) 04522R200 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desi |
|
| July 17, 2024 |
Exhibit 99.1 PRESS RELEASE ASLAN PHARMACEUTICALS ANNOUNCES IT HAS FILED FOR VOLUNTARY LIQUIDATION OF ITS SOLE OPERATING SUBSIDIARY AND IS COMMENCING STEPS TO PLACE ITSELF INTO VOLUNTARY LIQUIDATION - Following a thorough review of all strategic alternatives, ASLAN Pharmaceuticals Pte Ltd, the sole operating subsidiary of ASLAN Pharmaceuticals, has filed for voluntary liquidation - Quantuma (Singap |
|
| July 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 July 17, 2024 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant’s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organization) 3 Temasek Avenue |
|
| July 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 July 15, 2024 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant’s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organization) 3 Temasek Avenue |
|
| July 15, 2024 |
Exhibit 99.1 PRESS RELEASE ASLAN PHARMACEUTICALS ANNOUNCES RECEIPT OF NASDAQ DELISTING DETERMINATION; HAS DETERMINED NOT TO APPEAL San Mateo, California, and Singapore, July 15, 2024 – ASLAN Pharmaceuticals (“ASLAN” or the “Company”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced tha |
|
| June 18, 2024 |
ASLAN Pharmaceuticals Limited 3 Temasek Avenue Level 18 Centennial Tower Singapore 039190 ASLAN Pharmaceuticals Limited 3 Temasek Avenue Level 18 Centennial Tower Singapore 039190 June 18, 2024 VIA EDGAR U. |
|
| June 14, 2024 |
As filed with the U.S. Securities and Exchange Commission on June 14, 2024 As filed with the U.S. Securities and Exchange Commission on June 14, 2024 Registration No. 333-271460 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 3 TO FORM F-6 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 For Depositary Shares Evidenced by American Depositary Receipts ASLAN Pharmaceuticals Limited (Exact name of issuer of deposited securities |
|
| June 14, 2024 |
Certification under Rule 466 The depositary, JPMorgan Chase Bank, N.A. represents and certifies the following: (1) That it previously had filed a registration statement on Form F-6 (ASLAN Pharmaceuticals Limited, No. 333-271460) that the Commission declared effective, with terms of deposit identical to the terms of deposit of this registration statement. (2) That its ability to designate the date |
|
| June 14, 2024 |
ASLAN PHARMACEUTICALS ANNOUNCES PLAN TO IMPLEMENT ADS RATIO CHANGE Exhibit 99.1 PRESS RELEASE ASLAN PHARMACEUTICALS ANNOUNCES PLAN TO IMPLEMENT ADS RATIO CHANGE San Mateo, California, and Singapore, June 14, 2024 - ASLAN Pharmaceuticals (“ASLAN” or the “Company”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it plans to change the ratio of the |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 June 14, 2024 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant’s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organization) 3 Temasek Avenue |
|
| June 14, 2024 |
J.P.Morgan J.P.Morgan AMENDMENT NO. 2 dated as of June , 2024 (the "Amendment"), to the Amended and Restated Deposit Agreement dated as of September 8, 2020 (as previously and further amended from time to time, the "Deposit Agreement") among ASLAN Pharmaceuticals Limited and it successors (the “Company”), JPMorgan Chase Bank, N.A., as depositary (the "Depositary") and all Holders and Beneficial Ow |
|
| June 12, 2024 |
As filed with the Securities and Exchange Commission on June 12, 2024 Form F-3 Table of Contents As filed with the Securities and Exchange Commission on June 12, 2024 Registration No. |
|
| June 12, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE FORM F-3 (Form Type) ASLAN Pharmaceuticals Limited (Exact Name of Registrant as Specified in its Charter) Not Applicable (Translation of Registrant’s Name into English) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(2) Proposed Maximum Offering Price Per Unit(3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity Ordinary shares, par value $0. |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 May 31, 2024 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant’s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organization) 3 Temasek Avenue |
|
| May 31, 2024 |
THIRD Amendment and forbearance Loan, Guaranty and security agreement Exhibit 4.1 THIRD Amendment and forbearance to Loan, Guaranty and security agreement This Third Amendment and Forbearance to Loan, Guaranty, and Security Agreement (this “Amendment”) is entered into this 29th day of May, 2024, by and among (a) ASLAN PHARMACEUTICALS (USA) INC., a Delaware corporation (“Borrower Representative”), ASLAN PHARMACEUTICALS LIMITED, an exempted company incorporated under |
|
| May 31, 2024 |
WARRANT TO PURCHASE ORDINARY SHARES Exhibit 4.2 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY U.S. STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM A |
|
| May 9, 2024 |
Exhibit 99.1 PRESS RELEASE ASLAN PHARMACEUTICALS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Positive interim data readout from 22 patients in TREK-DX study of eblasakimab showed unprecedented efficacy data compared to prior atopic dermatitis (AD) studies with biologics: 60.0% of dupilumab-experienced AD patients treated with 400mg eblasakimab weekly achieved EASI- |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 May 9, 2024 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant’s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organization) 3 Temasek Avenue L |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 May 7, 2024 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant’s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organization) 3 Temasek Avenue L |
|
| May 7, 2024 |
Exhibit 99.1 PRESS RELEASE ASLAN PHARMACEUTICALS TO PRESENT ADDITIONAL DATA FROM INTERIM ANALYSIS OF TREK-DX PHASE 2 STUDY OF EBLASAKIMAB IN DUPILUMAB-EXPERIENCED ATOPIC DERMATITIS PATIENTS DURING VIRTUAL KOL EVENT - New positive data from an additional analysis of dupilumab-experienced patients treated with eblasakimab 400mg, weekly over 16 weeks further support the recent finding that some AD pa |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 April 22, 2024 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant’s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organization) 3 Temasek Avenu |
|
| April 22, 2024 |
Exhibit 99.1 PRESS RELEASE ASLAN PHARMACEUTICALS ANNOUNCES POSITIVE INTERIM RESULTS FROM PHASE 2 STUDY OF EBLASAKIMAB IN DUPILUMAB-EXPERIENCED ATOPIC DERMATITIS PATIENTS - Interim readout of 22 patients shows unprecedented efficacy data compared to prior atopic dermatitis (AD) studies with biologics: 60.0% of dupilumab-experienced AD patients treated with 400mg eblasakimab weekly achieved EASI-90 |
|
| April 19, 2024 |
ASLAN PHARMACEUTICALS ANNOUNCES RECEIPT OF NASDAQ NOTICE Exhibit 99.1 PRESS RELEASE ASLAN PHARMACEUTICALS ANNOUNCES RECEIPT OF NASDAQ NOTICE San Mateo, California, and Singapore, April 19, 2024 - ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it received a letter (the “Letter”) on April 18, 2024 from The Nasdaq |
|
| April 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 April 19, 2024 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant’s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organization) 3 Temasek Avenu |
|
| April 12, 2024 |
Exhibit 99.1 PRESS RELEASE ASLAN PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - In a preliminary review of blinded data from the ongoing TREK-DX study, 45% (10/22) of patients achieved at least a 90% reduction in their EASI score (EASI-90) after 16 weeks. 56% (5/9) of patients with prior inadequate response to dupilumab achieved EASI-90 |
|
| April 12, 2024 |
AMENDMENT NO. 2 TO THE OPEN MARKET SALE AGREEMENTSM Exhibit 99.1 AMENDMENT NO. 2 TO THE OPEN MARKET SALE AGREEMENTSM April 12, 2024 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: This Amendment No. 2 to the Open Market Sale AgreementSM (this “Amendment No. 2”) is entered into as of the date first written above by ASLAN Pharmaceuticals Limited, an exempted company incorporated with limited liability in the Cayman Isl |
|
| April 12, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) ASLAN Pharmaceuticals Limited (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(2) Proposed Maximum Offering Price Per Unit(3) Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee Equity ASLAN Pharmaceuticals Limited 2020 Equity Incentive Plan Ordinary Shares, $0. |
|
| April 12, 2024 |
DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT Exhibit 2.6 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT As of December 31, 2023, ASLAN Pharmaceuticals Limited, or “we,” “us,” and “our”, had the following series of securities registered pursuant to Section 12(b) of the Securities Exchange Act, as amended, or Exchange Act: Title of each class Trading symbol Name of each exchange on which registered American Depositar |
|
| April 12, 2024 |
American Depositary Shares representing Ordinary Shares Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-270835 PROSPECTUS SUPPLEMENT (To Prospectus Dated April 6, 2023) $12,000,000 American Depositary Shares representing Ordinary Shares We have entered into a certain Open Market Sale AgreementSM, dated as of October 9, 2020, as amended, or Sales Agreement, with Jefferies LLC, or Jefferies, relating to American Depositary Shares, |
|
| April 12, 2024 |
Exhibit 4.18 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED BECAUSE THE REGISTRANT HAS DETERMINED THE INFORMATION IS NOT MATERIAL AND IS THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 3 Temasek Avenue Level 18 Singapore 039190 t +65 6817 9598 www.aslanpharma.com To: Zenyaku Kogyo Co., Ltd. 6-15, Otsuka 5-Chome, Bunkyo-ku, Tokyo, 112-8650, Japan Attn: |
|
| April 12, 2024 |
Exhibit 97.1 Incentive Compensation Recoupment Policy Version: v1.0 Effective Date: 2 October 2023 Approved by: 13 March 2024 1. Introduction The Remuneration Committee (the “Remuneration Committee”) of the Board of Directors (the “Board”) of ASLAN Pharmaceuticals Limited, an exempted company incorporated in the Cayman Islands with limited liability (the “Company”), has determined that it is in th |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| April 12, 2024 |
Exhibit 12.2 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Kiran Asarpota, certify that: 1. I have reviewed this annual report on Form 20-F of ASLAN Pharmaceuticals Limited (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a mate |
|
| April 12, 2024 |
Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement Nos. 333-254768, 333-270835, 333-270837 and 333-278217 on Form-3 and Registration Statement Nos. 333-252118, 333-263843 and 333-270832 on Form S-8 of our reports dated April 12, 2024, relating to the financial statements of ASLAN Pharmaceuticals Limited and t |
|
| April 12, 2024 |
Exhibit 12.1 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Carl Firth, certify that: 1. I have reviewed this annual report on Form 20-F of ASLAN Pharmaceuticals Limited (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material |
|
| April 12, 2024 |
Exhibit 4.17 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED BECAUSE THE REGISTRANT HAS DETERMINED THE INFORMATION IS NOT MATERIAL AND IS THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. COLLABORATIVE DEVELOPMENT & COMMERCIALISATION AGREEMENT RELATING TO EBLASAKIMAB IN JAPAN BETWEEN ASLAN Pharmaceuticals Pte. Ltd. AND Zenyaku Kogyo Co., Ltd. Dated: 22nd |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 April 12, 2024 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant’s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organisation) 3 Temasek Avenu |
|
| April 12, 2024 |
As filed with the Securities and Exchange Commission on April 12, 2024 As filed with the Securities and Exchange Commission on April 12, 2024 Registration No. |
|
| April 12, 2024 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), Carl Firth, Ph.D., Chief Executive Officer of ASLAN Pharmaceuticals Limited (the “Company”), hereby certifies that, to the |
|
| April 12, 2024 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), Kiran Asarpota, Chief Operating Officer of ASLAN Pharmaceuticals Limited (the “Company”), hereby certifies that, to the bes |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 April 12, 2024 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant’s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organisation) 3 Temasek Avenu |
|
| March 28, 2024 |
ASLAN Pharmaceuticals Limited 3 Temasek Avenue Level 18 Centennial Tower Singapore 039190 ASLAN Pharmaceuticals Limited 3 Temasek Avenue Level 18 Centennial Tower Singapore 039190 March 28, 2024 VIA EDGAR U. |
|
| March 25, 2024 |
As filed with the Securities and Exchange Commission on March 25, 2024 Table of Contents As filed with the Securities and Exchange Commission on March 25, 2024 Registration No. |
|
| March 25, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE FORM F-3 (Form Type) ASLAN Pharmaceuticals Limited (Exact Name of Registrant as Specified in its Charter) Not Applicable (Translation of Registrant’s Name into English) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(2) Proposed Maximum Offering Price Per Unit(3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity Ordinary shares, par value $0. |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ASLAN Pharmaceuticals Limited (Name of Issuer) Ordinary shares, par value $0.01 per share (Title of Class of Securities) 04522R200** (CUSIP Number) March 12, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa |
|
| March 21, 2024 |
EX-99.1 2 ea020219701ex99-1aslan.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agr |
|
| March 19, 2024 |
SC 13G 1 sch13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ASLAN Pharmaceuticals Limited (Name of Issuer) Ordinary Shares, par value $0.01 per share (Title of Class of Securities) 04522R200 (CUSIP Number) March 14, 2024 (Date of Event which Requires Filing of this Statement) Check the appropri |
|
| March 19, 2024 |
EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Ordinary Shares, par value $0.01 per share, of ASLAN Pharmaceuticals Limited shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit |
|
| March 14, 2024 |
5,000,000 American Depositary Shares Representing 125,000,000 Ordinary Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-270835 PROSPECTUS SUPPLEMENT (To Prospectus Dated April 6, 2023) 5,000,000 American Depositary Shares Representing 125,000,000 Ordinary Shares We are offering 5,000,000 American Depositary Shares, or ADSs, representing 125,000,000 ordinary shares, nominal or par value $0.01 per share, at an offering price of $1.00 per ADS. Each ADS represents t |
|
| March 13, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”), dated as of March 12, 2024, is between ASLAN Pharmaceuticals Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 March 13, 2024 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant’s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organisation) 3 Temasek Avenu |
|
| March 13, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| March 13, 2024 |
ASLAN PHARMACEUTICALS ANNOUNCES $5 MILLION REGISTERED DIRECT OFFERING Exhibit 99.1 PRESS RELEASE ASLAN PHARMACEUTICALS ANNOUNCES $5 MILLION REGISTERED DIRECT OFFERING San Mateo, California, and Singapore, March 12, 2024 – ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has entered into a definitive agreement for the p |
|
| March 11, 2024 |
Exhibit 99.1 PRESS RELEASE ASLAN PHARMACEUTICALS PROVIDES TREK-DX STUDY UPDATE AND HIGHLIGHTS potENTIAL of EBLASAKIMAB in DUPILUMAB-EXPERIENCED ATOPIC DERMATITIS PATIENTS - TREK-DX, the first randomized, double-blind, placebo-controlled study to be conducted in a dupilumab-experienced atopic dermatitis (AD) patient population, has started enrolling patients in the US under an updated protocol; new |
|
| March 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 March 11, 2024 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant’s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organization) 3 Temasek Avenu |
|
| February 14, 2024 |
SC 13G/A 1 sc13ga107422asln02142024.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 ASLAN Pharmaceuticals Limited (Name of Issuer) Ordinary Shares, pa |
|
| February 14, 2024 |
SC 13G/A 1 ef20021585sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Aslan Pharmaceuticals Limited (Name of Issuer) Ordinary Shares, par value $0.01 per share (Title of Class of Securities) 04522R200** (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this St |
|
| January 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 January 24, 2024 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant’s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organisation) 3 Temasek Ave |
|
| January 24, 2024 |
Exhibit 99.1 THE COMPANIES ACT (AS AMENDED) of the Cayman islands Company Limited by Shares Twelfth AMENDED AND RESTATED MEMORANDUM and ARTICLES OF ASSOCIATION OF ASLAN PHARMACEUTICALS limited (ADOPTED BY SPECIAL RESOLUTION PASSED ON 24 January 2024) Ref: JT/MK/A6231-S09395 THE COMPANIES ACT (AS AMENDED) COMPANY LIMITED BY SHARES Twelfth amended and restated MEMORANDUM of ASSOCIATION OF ASLAN PHAR |
|
| January 8, 2024 |
EX-99.1 Exhibit 99.1 PRESS RELEASE ASLAN PHARMACEUTICALS ANNOUNCES RECEIPT OF NASDAQ DEFICIENCY NOTICE REGARDING MINIMUM BID PRICE REQUIREMENT San Mateo, California, and Singapore, January 8, 2024 - ASLAN Pharmaceuticals (NASDAQ: ASLN) (“ASLAN” or the “Company”), announced today that on January 5, 2024, it received a written notice (the “Notice”) from the Listing Qualifications Department of The N |
|
| January 8, 2024 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 January 8, 2024 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant’s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organization) 3 Tem |
|
| January 2, 2024 |
Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| December 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 December 22, 2023 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant’s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organization) 3 Temasek Av |
|
| December 22, 2023 |
Exhibit 99.2 THE COMPANIES ACT (AS AMENDED) of the Cayman islands Company Limited by Shares Twelfth AMENDED AND RESTATED MEMORANDUM and ARTICLES OF ASSOCIATION OF ASLAN PHARMACEUTICALS limited (ADOPTED BY SPECIAL RESOLUTION PASSED ON [DATE]) Ref: JT/MK/A6231-S09395 THE COMPANIES ACT (AS AMENDED) COMPANY LIMITED BY SHARES Twelfth amended and restated MEMORANDUM of ASSOCIATION OF ASLAN PHARMACEUTICA |
|
| December 22, 2023 |
ASLAN Pharmaceuticals Limited (the "Company") Notice of Extraordinary General Meeting of the Company Exhibit 99.1 c/o Walkers Corporate Limited 190 Elgin Avenue, George Town Grand Cayman KY1-9008 Cayman Islands www.aslanpharma.com ASLAN Pharmaceuticals Limited (the "Company") Notice of Extraordinary General Meeting of the Company NOTICE IS HEREBY GIVEN that an Extraordinary General Meeting of the Company (the "Meeting") will be held on the 24th day of January, 2024, at 9:00 am at 3 Temasek Avenue |
|
| December 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 December 8, 2023 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant’s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organization) 3 Temasek Ave |
|
| December 8, 2023 |
SECOND Amendment Loan, Guaranty and security agreement Exhibit 4.1 SECOND Amendment to Loan, Guaranty and security agreement This Second Amendment to Loan, Guaranty, and Security Agreement (this “Amendment”) is entered into this 6th day of December, 2023, by and among (a) ASLAN PHARMACEUTICALS (USA) INC., a Delaware corporation (“Borrower Representative”), ASLAN PHARMACEUTICALS LIMITED, an exempted company incorporated under the laws of the Cayman Isl |
|
| October 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 October 27, 2023 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant’s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organization) 3 Temasek Ave |
|
| October 27, 2023 |
Exhibit 99.1 PRESS RELEASE ASLAN PHARMACEUTICALS REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Positive topline data reported in July from TREK-AD, a Phase 2b study of eblasakimab in moderate-to-severe atopic dermatitis, met the primary endpoint across three dosing arms; the study established eblasakimab's potential to deliver a monthly dosing regime from initiation |
|
| October 24, 2023 |
Exhibit 99.1 PRESS RELEASE ASLAN PHARMACEUTICALS TO CO-HOST KOL PANEL DISCUSSION TODAY ON CHANGES IN THE CLINICAL TRIAL AND TREATMENT LANDSCAPE FOR ATOPIC DERMATITIS - Discussion featuring KOLs Dr Jonathan Silverberg, Dr April W. Armstrong, and a leading CRO will explore “The Changing Face of Atopic Dermatitis: How the Clinical Trial and Treatment Landscape Has Changed in the Seven Years Following |
|
| October 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 October 24, 2023 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant’s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organization) 3 Temasek Ave |
|
| October 16, 2023 |
Exhibit 99.1 PRESS RELEASE ASLAN PHARMACEUTICALS PRESENTS NEW DATA FROM PHASE 2B STUDY OF EBLASAKIMAB IN ATOPIC DERMATITIS IN LATE BREAKER PRESENTATION AT 32ND EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY CONGRESS - Data presented during the late-breaker oral presentation of the TREK-AD study demonstrate eblasakimab’s potential as the first biologic in moderate-to-severe atopic dermatitis to de |
|
| October 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 October 16, 2023 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant’s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organization) 3 Temasek Ave |
|
| August 18, 2023 |
Exhibit 99.1 PRESS RELEASE (restated August 18, 2023) EBLASAKIMAB MONTHLY DOSING SHOWS POTENTIAL FOR BEST-IN-CLASS THERAPY IN POSITIVE PHASE 2B STUDY IN ATOPIC DERMATITIS • Eblasakimab is the first biologic in moderate-to-severe atopic dermatitis to demonstrate a competitive efficacy profile with once-monthly dosing from initiation comparable to once every two weeks, supporting advancement to Phas |
|
| August 18, 2023 |
Form 6-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 July 6, 2023 (as amended on August 18, 2023) (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant’s name into English) CAYMAN ISLANDS (Jurisdiction of inc |
|
| August 18, 2023 |
Eblasakimab Phase 2b TREK-AD Topline readout Exhibit 99.2 Eblasakimab Phase 2b TREK-AD Topline readout 6 July 2023 Restated 18 August 2023 NASDAQ: ASLN Eblasakimab Phase 2b TREK-AD Topline readout 6 July 2023 Restated 18 August 2023 NASDAQ: ASLN Legal disclaimer This presentation contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of ASLAN Pharmaceuticals Limited (the “Com |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 August 11, 2023 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant’s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organization) 3 Temasek Aven |
|
| August 11, 2023 |
Exhibit 99.2 ASLAN PHARMACEUTICALS LIMITED AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In U.S. Dollars, other than shares or share data, or otherwise noted) (Unaudited) December 31, 2022 June 30, 2023 ASSETS CURRENT ASSETS Cash and cash equivalents (Note 6) $ 56,902,077 $ 40,943,949 Trade receivable (Note 7) — 12,000,000 Other assets (Note 8) 3,976,350 2,135,067 Total current assets 60 |
|
| August 11, 2023 |
Exhibit 99.1 PRESS RELEASE ASLAN PHARMACEUTICALS REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Positive topline data reported in July from TREK-AD, a Phase 2b study of eblasakimab that met the primary endpoint across three dose arms with statistical significance. The data established eblasakimab, a potential first-in-class antibody, as the first biologic in moderate |
|
| July 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 July 20, 2023 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant’s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organization) 3 Temasek Avenue |
|
| July 13, 2023 |
Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| July 6, 2023 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 July 6, 2023 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant’s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organization) 3 Temase |
|
| July 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 July 6, 2023 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant’s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organization) 3 Temasek Avenue |
|
| July 6, 2023 |
American Depositary Shares representing Ordinary Shares 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-252575 AMENDMENT NO. 1 DATED JULY 6, 2023 To Prospectus Supplement Dated September 13, 2022 (To Prospectus Dated February 11, 2021) $85,000,000 American Depositary Shares representing Ordinary Shares This Amendment No. 1 to Prospectus Supplement, or this Amendment, amends our prospectus supplement dated September 13, 2022, or the Prospect |
|
| July 6, 2023 |
Exhibit 99.1 PRESS RELEASE EBLASAKIMAB MONTHLY DOSING SHOWS POTENTIAL FOR BEST-IN-CLASS THERAPY IN POSITIVE PHASE 2B STUDY IN ATOPIC DERMATITIS - Eblasakimab is the first biologic in moderate-to-severe atopic dermatitis to demonstrate a competitive efficacy profile with once-monthly dosing from initiation comparable to once every two weeks, supporting advancement to Phase 3. - 600mg eblasakimab do |
|
| July 3, 2023 |
FIRST AMENDMENT LOAN, GUARANTY AND SECURITY AGREEMENT EX-10.1 Exhibit 10.1 FIRST AMENDMENT TO LOAN, GUARANTY AND SECURITY AGREEMENT This First Amendment to Loan, Guaranty, and Security Agreement (this “Amendment”) is entered into this 30th day of June, 2023, by and among (a) ASLAN PHARMACEUTICALS (USA) INC., a Delaware corporation (“Borrower Representative”), ASLAN PHARMACEUTICALS LIMITED, an exempted company incorporated under the laws of the Cayman |
|
| July 3, 2023 |
AMENDMENT NO. 1 TO WARRANT TO PURCHASE ORDINARY SHARES EX-4.1 Exhibit 4.1 AMENDMENT NO. 1 TO WARRANT TO PURCHASE ORDINARY SHARES THIS AMENDMENT NO. 1 TO WARRANT TO PURCHASE ORDINARY SHARES is made this 30th day of June, 2023, by and between K2 HealthVentures Equity Trust LLC (“Holder”) and ASLAN Pharmaceuticals Limited, a Cayman Islands exempted company with registration number 289175 (the “Company”). WHEREAS, Holder is the holder of that certain Warr |
|
| July 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 July 3, 2023 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant’s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organization) 3 Temasek Avenue |
|
| June 22, 2023 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 June 22, 2023 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant’s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organization) 3 Temas |
|
| June 22, 2023 |
EX-99.1 Exhibit 99.1 PRESS RELEASE ASLAN PHARMACEUTICALS ENTERS INTO A STRATEGIC LICENSING DEAL WITH ZENYAKU KOGYO FOR THE DEVELOPMENT AND COMMERCIALIZATION OF EBLASAKIMAB IN JAPAN • ASLAN will receive up to $15 million in upfront and near-term payments and up to an additional $123.5 million based on development and commercial milestones plus tiered royalties on sales in percentages ranging up to |
|
| April 28, 2023 |
Exhibit 99.1 PRESS RELEASE ASLAN PHARMACEUTICALS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Data readout for TREK-AD Phase 2b study of eblasakimab on track for early July 2023 - Four abstracts on eblasakimab and farudodstat, including two late-breakers, to be presented at the 1st International Societies of Investigative Dermatology meeting May 10-13 in Tokyo - $20 |
|
| April 28, 2023 |
6-K 1 asln6-k-04282023.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 April 28, 2023 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant’s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation o |
|
| April 26, 2023 |
As filed with the U.S. Securities and Exchange Commission on April 26, 2023 As filed with the U.S. Securities and Exchange Commission on April 26, 2023 Registration No. 333- SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-6 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 For Depositary Shares Evidenced by American Depositary Receipts ASLAN Pharmaceuticals Limited (Exact name of issuer of deposited securities as specified in its charter) N/A (Trans |
|
| April 26, 2023 |
[FORM OF FACE OF ADR] No. of ADSs: Number Each ADS represents Twenty Five Shares CUSIP: AMERICAN DEPOSITARY RECEIPT evidencing AMERICAN DEPOSITARY SHARES representing ORDINARY SHARES of ASLAN PHARMACEUTICALS LIMITED (Incorporated under the laws of the Cayman Islands) JPMORGAN CHASE BANK, N.A., a national banking association organized under the laws of the United States of America, as depositary he |
|
| April 26, 2023 |
Ziegler, Ziegler & Associates LLP Counselors at Law 570 Lexington Avenue, Suite 2405 New York, New York 10022 (212) 319-7600 Telecopier (212) 319-7605 April 26, 2023 JPMorgan Chase Bank, N. |
|
| April 26, 2023 |
Certification under Rule 466 The depositary, JPMorgan Chase Bank, N.A. represents and certifies the following: (1) That it previously had filed a registration statement on Form F-6 (ASLAN Pharmaceuticals Limited, No. 333-224273) that the Commission declared effective, with terms of deposit identical to the terms of deposit of this registration statement. (2) That its ability to designate the date |
|
| April 4, 2023 |
ASLAN Pharmaceuticals Limited 3 Temasek Avenue Level 18 Centennial Tower Singapore 039190 CORRESP ASLAN Pharmaceuticals Limited 3 Temasek Avenue Level 18 Centennial Tower Singapore 039190 April 4, 2023 VIA EDGAR U. |
|
| April 4, 2023 |
ASLAN Pharmaceuticals Limited 3 Temasek Avenue Level 18 Centennial Tower Singapore 039190 CORRESP ASLAN Pharmaceuticals Limited 3 Temasek Avenue Level 18 Centennial Tower Singapore 039190 April 4, 2023 VIA EDGAR U. |
|
| March 24, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) ASLAN Pharmaceuticals Limited (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary Shares, $0. |
|
| March 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 March 24, 2023 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant’s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organization) 3 Temasek Avenu |
|
| March 24, 2023 |
Exhibit 12.1 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Carl Firth, certify that: 1. I have reviewed this annual report on Form 20-F of ASLAN Pharmaceuticals Limited (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material |
|
| March 24, 2023 |
As filed with the Securities and Exchange Commission on March 24, 2023 As filed with the Securities and Exchange Commission on March 24, 2023 Registration No. |
|
| March 24, 2023 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), Kiran Asarpota, Chief Operating Officer of ASLAN Pharmaceuticals Limited (the “Company”), hereby certifies that, to the bes |
|
| March 24, 2023 |
As filed with the Securities and Exchange Commission on March 24, 2023 Form F-3 Table of Contents As filed with the Securities and Exchange Commission on March 24, 2023 Registration No. |
|
| March 24, 2023 |
As filed with the Securities and Exchange Commission on March 24, 2023 Form F-3 Table of Contents As filed with the Securities and Exchange Commission on March 24, 2023 Registration No. |
|
| March 24, 2023 |
Exhibit 99.1 PRESS RELEASE ASLAN PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - TREK-AD Phase 2b study of eblasakimab fully enrolled, topline data readout expected early July 2023 - Phase 2 proof-of-concept trial of farudodstat in alopecia areata expected to commence in the second quarter of 2023 with topline data readout expected in the |
|
| March 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 24, 2023 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), Carl Firth, Ph.D., Chief Executive Officer of ASLAN Pharmaceuticals Limited (the “Company”), hereby certifies that, to the |
|
| March 24, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) ASLAN Pharmaceuticals Limited (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity Ordinary shares, par value $0. |
|
| March 24, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) ASLAN Pharmaceuticals Limited (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity Ordinary shares, par value $0. |
|
| March 24, 2023 |
Description Of Securities Registered Under Section 12 of the Exchange Act. Exhibit 2.5 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT As of December 31, 2022, ASLAN Pharmaceuticals Limited, or “we,” “us,” and “our”, had the following series of securities registered pursuant to Section 12(b) of the Securities Exchange Act, as amended, or Exchange Act: Title of each class Trading symbol Name of each exchange on which registered American Depositar |
|
| March 24, 2023 |
Exhibit 12.2 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Kiran Asarpota, certify that: 1. I have reviewed this annual report on Form 20-F of ASLAN Pharmaceuticals Limited (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a mate |
|
| March 24, 2023 |
Consent of Independent Registered Public Accounting Firm, Deloitte & Touche LLP Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement Nos. 333-252575 and 333-254768 on Form-3 and Registration Statement Nos. 333-252118 and 333-263843 on Form S-8 of our report dated March 24, 2023, relating to the consolidated financial statements of ASLAN Pharmaceuticals Limited appearing in this Annual Repo |
|
| March 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Aslan Pharmaceuticals Limited (Name of Issuer) Ordinary Shares, par value $0.01 per share (Title of Class of Securities) 04522R101** (CUSIP Number) February 24, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| March 20, 2023 |
CUSIP No. 04522R101 Page 9 of 9 Pages EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G with respect to the Ordinary Shares of Aslan Pharmaceuticals Limited, dated as of March 20, 2023, is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in acco |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 March 10, 2023 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant’s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organization) 3 Temasek Avenu |
|
| March 10, 2023 |
ASLAN PHARMACEUTICALS ANNOUNCES PLAN TO IMPLEMENT ADS RATIO CHANGE Exhibit 99.1 PRESS RELEASE ASLAN PHARMACEUTICALS ANNOUNCES PLAN TO IMPLEMENT ADS RATIO CHANGE San Mateo, California, and Singapore, March 10, 2023 – ASLAN Pharmaceuticals (“ASLAN”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it plans to change the ratio of the American Deposi |
|
| March 6, 2023 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated March 6, 2023 with respect to the Ordinary Shares, par value $0.01 per share of ASLAN Pharmaceuticals Limited, a Cayman Islands corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in acc |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 ASLAN Pharmaceuticals Limited (Name of Issuer) Ordinary Shares, par value $0.01 per share (Title of Class of Securities) 04522R1012 (CUSIP |
|
| March 3, 2023 |
Certification under Rule 466 The depositary, JPMorgan Chase Bank, N.A. represents and certifies the following: (1) That it previously had filed a registration statement on Form F-6 (ASLAN Pharmaceuticals Limited, No. 333-224273) that the Commission declared effective, with terms of deposit identical to the terms of deposit of this registration statement. (2) That its ability to designate the date |
|
| March 3, 2023 |
J.P.Morgan J.P.Morgan AMENDMENT NO. 1 dated as of , 2023 (the "Amendment"), to the Amended and Restated Deposit Agreement dated as of September 8, 2020 (as amended from time to time, the "Deposit Agreement") among ASLAN Pharmaceuticals Limited and it successors (the “Company”), JPMorgan Chase Bank, N.A., as depositary (the "Depositary") and all Holders and Beneficial Owners from time to time of Am |
|
| March 3, 2023 |
As filed with the U.S. Securities and Exchange Commission on March 3, 2023 As filed with the U.S. Securities and Exchange Commission on March 3, 2023 Registration No. 333-224273 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO FORM F-6 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 For Depositary Shares Evidenced by American Depositary Receipts ASLAN Pharmaceuticals Limited (Exact name of issuer of deposited securities |
|
| February 24, 2023 |
EX-99.5 Exhibit 99.5 FINAL FORM NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO |
|
| February 24, 2023 |
EX-99.3 Exhibit 99.3 FINAL FORM NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO |
|
| February 24, 2023 |
EX-99.6 Exhibit 99.6 FINAL FORM NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO |
|
| February 24, 2023 |
EX-99.4 Exhibit 99.4 FINAL FORM NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO |
|
| February 24, 2023 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 February 24, 2023 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant’s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organization) 3 T |
|
| February 24, 2023 |
EX-99.1 Exhibit 99.1 EXECUTION VERSION UNIT PURCHASE AGREEMENT This Unit Purchase Agreement (this “Agreement”) is dated as of February 24, 2023, by and among ASLAN Pharmaceuticals Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assig |
|
| February 24, 2023 |
EX-99.2 Exhibit 99.2 FINAL FORM NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO |
|
| February 14, 2023 |
ASLN / ASLAN Pharmaceuticals Limited / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 1 Passive Investment SC 13G/A 1 asln282314sc13ga1.htm AMENDMENT NO. 1 Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* ASLAN Pharmaceuticals Limited (Name of Issuer) Ordinary Shares as represented by American Depository Shares (“ADSs”), par value $0.01 per ordinary share** (Title of Class of Securities) 04522R101*** (CUSIP Number) Decem |
|
| February 14, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ASLAN Pharmaceuticals Limited (Name of Issuer) Ordinary Shares, par value $0.01 per share (Title of Class of Securities) 04522R101** (CUSIP Number) December 31, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rul |
|
| January 31, 2023 |
Exhibit 99.1 THE COMPANIES ACT (AS AMENDED) of the Cayman islands Company Limited by Shares ELEVENTH AMENDED AND RESTATED MEMORANDUM and ARTICLES OF ASSOCIATION OF ASLAN PHARMACEUTICALS limited (ADOPTED BY SPECIAL RESOLUTION PASSED ON 31 January 2023) Ref: JT/MK/A6231-S09395 13123451.2.A6231.S09770 THE COMPANIES ACT (AS AMENDED) COMPANY LIMITED BY SHARES ELEVENTH amended and restated MEMORANDUM of |
|
| January 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 January 31, 2023 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant’s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organisation) 3 Temasek Ave |
|
| January 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 January 4, 2023 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant’s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organisation) 3 Temasek Aven |
|
| January 4, 2023 |
Exhibit 99.1 PRESS RELEASE ASLAN PHARMACEUTICALS AND THERMO FISHER SCIENTIFIC ANNOUNCE PARTNERSHIP TO MANUFACTURE HIGH CONCENTRATION FORMULATION OF EBLASAKIMAB FOR FUTURE STUDIES - Thermo Fisher Scientific to provide biologic manufacturing expertise and scale-up capacity to manage the clinical supply of eblasakimab for future Phase 3 studies - A high concentration formulation of eblasakimab (200mg |
|
| December 21, 2022 |
Exhibit 99.2 THE COMPANIES ACT (AS AMENDED) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES ELEVENTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION OF ASLAN PHARMACEUTICALS LIMITED (ADOPTED BY SPECIAL RESOLUTION PASSED ON [DATE]) REF: JT/MK/A6231-S09395 13123451.2.A6231.S09770 THE COMPANIES ACT (AS AMENDED) COMPANY LIMITED BY SHARES ELEVENTH AMENDED AND RESTATED MEMORANDUM OF ASSOCIAT |
|
| December 21, 2022 |
ASLAN Pharmaceuticals Limited (the "Company") Notice of Extraordinary General Meeting of the Company Exhibit 99.1 c/o Walkers Corporate Limited 190 Elgin Avenue, George Town Grand Cayman KY1-9008 Cayman Islands www.aslanpharma.com ASLAN Pharmaceuticals Limited (the "Company") Notice of Extraordinary General Meeting of the Company NOTICE IS HEREBY GIVEN that an Extraordinary General Meeting of the Company (the "Meeting") will be held on the 31st day of January, 2023, at 9:00 am at 3 Temasek Avenue |
|
| December 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 December 21, 2022 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant’s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organisation) 3 Temasek Av |
|
| October 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 October 28, 2022 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant?s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organisation) 3 Temasek Ave |
|
| October 28, 2022 |
ASLAN Pharmaceuticals Limited CONSOLIDATED BALANCE SHEETS (In US Dollars) Exhibit 99.1 PRESS RELEASE ASLAN PHARMACEUTICALS REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Company maintains healthy operating position with US$68.9 million in cash, cash equivalents and short-term investments as of September 30, 2022; expected runway through late 2023 - New TREK-DX clinical program studying eblasakimab?s potential in dupilumab experienced atopic |
|
| September 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 September 28, 2022 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant?s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organisation) 3 Temasek A |
|
| September 14, 2022 |
Exhibit 99.1 PRESS RELEASE ASLAN PHARMACEUTICALS COMMENCES CLINICAL PROGRAM TO STUDY EBLASAKIMAB IN DUPILUMAB-EXPERIENCED ATOPIC DERMATITIS PATIENTS - ASLAN plans to begin TREK-DX (TRials in EblasaKimab in Dupilumab eXperienced AD patients) in the fourth quarter of 2022 to evaluate the efficacy and safety of eblasakimab as an alternative biologic in atopic dermatitis (AD) patients who have discont |
|
| September 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 September 14, 2022 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant?s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organisation) 3 Temasek A |
|
| September 13, 2022 |
American Depositary Shares representing Ordinary Shares Filed pursuant to Rule 424(b)(5) Registration No. 333- 252575 PROSPECTUS SUPPLEMENT (To Prospectus Dated February 11, 2021) $21,500,000 American Depositary Shares representing Ordinary Shares We have entered into a certain Open Market Sale AgreementSM, dated as of October 9, 2020, as amended on September 13, 2022, or Sales Agreement, with Jefferies LLC, or Jefferies, relating to American Depositar |
|
| September 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 September 13, 2022 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant?s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organisation) 3 Temasek A |
|
| September 13, 2022 |
AMENDMENT NO. 1 TO THE OPEN MARKET SALE AGREEMENTSM Exhibit 99.1 AMENDMENT NO. 1 TO THE OPEN MARKET SALE AGREEMENTSM September 13, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: This Amendment No. 1 to the Open Market Sale AgreementSM (this ?Amendment?) is entered into as of the date first written above by ASLAN Pharmaceuticals Limited, an exempted company incorporated with limited liability in the Cayman Islan |
|
| September 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 September 8, 2022 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant?s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organisation) 3 Temasek Av |
|
| September 8, 2022 |
ASLAN PHARMACEUTICALS PRESENTS NEW DATA ON EBLASAKIMAB IN MULTIPLE POSTERS AT THE 31 Exhibit 99.1 PRESS RELEASE ASLAN PHARMACEUTICALS PRESENTS NEW DATA ON EBLASAKIMAB IN MULTIPLE POSTERS AT THE 31st ANNUAL EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (EADV) CONGRESS ? Data presented at EADV for the first time show eblasakimab suppresses downstream inflammatory biomarkers of atopic dermatitis, continuing 4-6 weeks after the last dose ? Notable improvements in quality-of-sleep me |
|
| August 12, 2022 |
Exhibit 99.1 PRESS RELEASE ASLAN PHARMACEUTICALS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Company maintains healthy operating position with US$78.1 million in cash, cash equivalents and short-term investments as of June 30, 2022, runway through late 2023 - Three abstracts showcasing new findings related to eblasakimab have been accepted as e-posters at the 31st |
|
| August 12, 2022 |
Exhibit 99.2 ASLAN PHARMACEUTICALS LIMITED AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In U.S. Dollars, other than shares or share data, or otherwise noted) (Unaudited) December 31, 2021 June 30, 2022 ASSETS CURRENT ASSETS Cash and cash equivalents (Note 6) $ 90,167,967 $ 61,576,463 Short-term investments ( Notes 7 and 12 ) ? 16,543,352 Total cash, cash equivalents, and short-term inve |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 August 12, 2022 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant?s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organization) 83 CLEMENCEAU |
|
| April 27, 2022 |
ASLAN Pharmaceuticals Limited CONSOLIDATED BALANCE SHEETS (In US Dollars) Exhibit 99.1 PRESS RELEASE ASLAN PHARMACEUTICALS REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Global Phase 2b trial for eblasakimab in moderate-to-severe atopic dermatitis (AD) progressing, multiple sites enrolling; topline data expected in the first half of 2023 - Alex Kaoukhov, MD, appointed as Chief Medical Officer, adding global pharma leadership experience ahea |
|
| April 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 April 27, 2022 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant?s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organization) 83 CLEMENCEAU A |
|
| April 21, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Ordinary Shares, $0.01 par value per share, of ASLAN Pharmaceuticals Limited and further agree to the filing of this Joint Filing Agreeme |
|
| April 21, 2022 |
Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| April 1, 2022 |
Exhibit 99.1 PRESS RELEASE ASLAN PHARMACEUTICALS ANNOUNCES RECEIPT OF NASDAQ DEFICIENCY NOTICE REGARDING MINIMUM BID PRICE REQUIREMENT Menlo Park, California, and Singapore, April 1, 2022 ? ASLAN Pharmaceuticals (NASDAQ: ASLN) ("ASLAN" or the "Company"), announced today that on March 28, 2022, it received a written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stoc |
|
| April 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 April 1, 2022 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant?s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organisation) 83 CLEMENCEAU AV |
|
| March 25, 2022 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), Kiran Asarpota, Chief Operating Officer of ASLAN Pharmaceuticals Limited (the “Company”), hereby certifies that, to the bes |
|
| March 25, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) ASLAN Pharmaceuticals Limited (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary Shares, $0. |
|
| March 25, 2022 |
Exhibit 12.1 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Carl Firth, certify that: 1. I have reviewed this annual report on Form 20-F of ASLAN Pharmaceuticals Limited (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material |
|
| March 25, 2022 |
ASLAN Pharmaceuticals Limited CONSOLIDATED BALANCE SHEETS (In US Dollars) Exhibit 99.1 PRESS RELEASE ASLAN PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Global Phase 2b trial for eblasakimab in moderate-to-severe atopic dermatitis (AD) underway with topline data expected in the first half of 2023 - New CMO appointed, adding senior global pharma experience to the leadership team - Company maintains strong oper |
|
| March 25, 2022 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), Carl Firth, Ph.D., Chief Executive Officer of ASLAN Pharmaceuticals Limited (the “Company”), hereby certifies that, to the |
|
| March 25, 2022 |
Description Of Securities Registered Under Section 12 of the Exchange Act. Exhibit 2.5 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT As of December 31, 2021, ASLAN Pharmaceuticals Limited, or ?we,? ?us,? and ?our?, had the following series of securities registered pursuant to Section 12(b) of the Securities Exchange Act, as amended, or Exchange Act: Title of each class Trading symbol Name of each exchange on which registered American Depositar |
|
| March 25, 2022 |
As filed with the Securities and Exchange Commission on March 25, 2022 As filed with the Securities and Exchange Commission on March 25, 2022 Registration No. |
|
| March 25, 2022 |
Consent of Independent Registered Public Accounting Firm, Deloitte & Touche LLP EX-15.1 8 asln-ex151794.htm EX-15.1 Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement Nos. 333-234405, 333-252575 and 333-254768 on Form F-3 and Registration Statement No. 333-252118 on Form S-8 of our report dated March 25, 2022, relating to the consolidated financial statements of ASLAN Pharmaceuticals Lim |
|
| March 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 March 25, 2022 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant?s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organisation) 83 CLEMENCEAU A |
|
| March 25, 2022 |
Exhibit 15.2 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement Nos. 333-234405, 333-252575 and 333-254768 on Form F-3 and Registration Statement No. 333-252118 on Form S-8 of our report dated April 16, 2020, relating to the consolidated financial statements of ASLAN Pharmaceuticals Limited appearing in the Annual Report |
|
| March 25, 2022 |
Exhibit 12.2 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Kiran Asarpota, certify that: 1. I have reviewed this annual report on Form 20-F of ASLAN Pharmaceuticals Limited (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a mate |
|
| March 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 15, 2022 |
ASLAN PHARMACEUTICALS APPOINTS DERMATOLOGY VETERAN DR ALEX KAOUKHOV AS CHIEF MEDICAL OFFICER Exhibit 99.1 PRESS RELEASE ASLAN PHARMACEUTICALS APPOINTS DERMATOLOGY VETERAN DR ALEX KAOUKHOV AS CHIEF MEDICAL OFFICER - Dermatologist with over twenty years of experience in senior biopharma roles in the US and Europe, including positions at Almirall, Allergan and Novartis - Strengthens leadership team as eblasakimab (also known as ASLAN004) moves into late-stage trials Menlo Park, California, a |
|
| March 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 March 15, 2022 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant?s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organisation) 83 CLEMENCEAU A |
|
| February 14, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ASLAN Pharmaceuticals Limited (Name of Issuer) Ordinary Shares, par value $0.01 per share (Title of Class of Securities) 04522R101** (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule |
|
| January 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 January 21, 2022 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant?s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organisation) 83 CLEMENCEAU |
|
| January 21, 2022 |
Exhibit 99.1 PRESS RELEASE ASLAN PHARMACEUTICALS INITIATES PHASE 2B STUDY OF ASLAN004 (EBLASAKIMAB) IN MODERATE-TO-SEVERE ATOPIC DERMATITIS - The TRials with EblasaKimab in Atopic Dermatitis (TREK-AD) study will evaluate the efficacy and safety of ASLAN004, now known as eblasakimab, a potential first-in-class antibody targeting the IL-13 receptor - This dose-ranging study is expected to enroll app |
|
| October 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 October 26, 2021 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant?s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organisation) 83 CLEMENCEAU |
|
| October 26, 2021 |
ASLAN Pharmaceuticals Limited CONSOLIDATED BALANCE SHEETS (In US Dollars) Exhibit 99.1 PRESS RELEASE ASLAN PHARMACEUTICALS REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - ASLAN004 met primary endpoint and key secondary efficacy endpoints in a Phase 1 Multiple-Ascending-Dose (MAD) trial in patients with moderate-to-severe atopic dermatitis (AD) - On track to initiate Phase 2b 300-patient clinical trial for ASLAN004 in 4Q 2021 - Company mainta |
|
| September 27, 2021 |
Exhibit 99.1 PRESS RELEASE ASLAN PHARMACEUTICALS ANNOUNCES POSITIVE DATA CONCLUSIVELY ESTABLISHING PROOF OF CONCEPT FOR ASLAN004 IN ATOPIC DERMATITIS - Topline data from multiple-ascending-dose study supports a potentially differentiated safety and efficacy profile - ASLAN004 achieved a statistically significant improvement (p<0.0251) versus placebo in the primary efficacy endpoint of percent chan |
|
| September 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION 6-K 1 asln-6k20210927.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 September 27, 2021 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant’s name into English) CAYMAN ISLANDS (Jurisdiction of incorporatio |
|
| August 6, 2021 |
Exhibit 12.1 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Carl Firth, certify that: 1) I have reviewed this Amendment No. 1 to the annual report on Form 20-F of ASLAN Pharmaceuticals Limited (the ?Company?); and 2) Based on my knowledge, this report does not contain any unt |
|
| August 6, 2021 |
Exhibit 15.2 ???? ???????????? 11073?????????100?20? Deloitte & Touche 20F, Taipei Nan Shan Plaza No. 100, Songren Rd., Xinyi Dist., Taipei 11073, Taiwan Tel: +886 (2) 2725-9988 Fax: +886 (2) 4051-6888 www.deloitte.com.tw CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement Nos. 333-234405, 333-252575 and 333-254768 on Form |
|
| August 6, 2021 |
EX-12.2 Exhibit 12.2 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Kiran Asarpota, certify that: 1) I have reviewed this Amendment No. 1 to the annual report on Form 20-F of ASLAN Pharmaceuticals Limited (the “Company”); and 2) Based on my knowledge, this report does not con |
|
| August 6, 2021 |
American Depositary Shares representing Ordinary Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-234405 AMENDMENT NO. 2 DATED AUGUST 6, 2021 To Prospectus Supplement Dated October 9, 2020 (To Prospectus Dated November 8, 2019) $85,000,000 American Depositary Shares representing Ordinary Shares This Amendment No. 2 to Prospectus Supplement, or this Amendment, amends our prospectus supplement dated October 9, 2020, or the Prospectus Suppleme |
|
| August 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 August 6, 2021 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant?s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organization) 83 CLEMENCEAU A |
|
| August 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F/A Amendment No. 1 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F/A Amendment No. 1 (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTI |
|
| August 6, 2021 |
Consent of Independent Registered Public Accounting Firm, Deloitte & Touche LLP, Singapore EX-15.1 4 d209830dex151.htm EX-15.1 Exhibit 15.1 Deloitte & Touche LLP Unique Entity No. T08LL0721A 6 Shenton Way OUE Downtown 2 #33-00 Singapore 068809 Tel: +65 6224 8288 Fax: +65 6538 6166 www.deloitte.com/sg CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement Nos. 333-234405, 333-252575 and 333-254768 on Form F-3 and Re |
|
| August 6, 2021 |
Exhibit 99.1 ASLAN PHARMACEUTICALS LIMITED AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In U.S. Dollars, other than shares or share data, or otherwise noted) (Unaudited) December 31, 2020 June 30, 2021 ASSETS CURRENT ASSETS Cash and cash equivalents (Note 6) $ 14,324,371 $ 94,120,158 Other receivables (Note 14) 528,841 ? Prepayments 511,208 615,212 Financial assets at fair value through |
|
| July 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 July 14, 2021 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant?s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organisation) 83 CLEMENCEAU AV |
|
| July 14, 2021 |
Warrant to Purchase Ordinary Shares. Exhibit 4.1 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR THE SECURITIES LAWS OF ANY U.S. STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM A |
|
| July 14, 2021 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT ASLAN PHARMACEUTICALS LIMITED TREATS AS PRIVATE OR CONFIDENTIAL LOAN, GUARANTY, AND SECURITY AGREEMENT This LOAN, GUARANTY, AND SECURITY AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this ? |
|
| May 11, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 May 11, 2021 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant?s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organisation) 83 CLEMENCEAU AVE |
|
| May 11, 2021 |
ASLAN Pharmaceuticals Limited CONSOLIDATED BALANCE SHEETS (In U.S. Dollars) Exhibit 99.1 PRESS RELEASE ASLAN PHARMACEUTICALS REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Next data readout for ASLAN004 in the treatment of patients with moderate to severe atopic dermatitis anticipated in the third quarter of 2021 - Phase 2b clinical trial for ASLAN004 expected to initiate in the second half of 2021 Singapore, 11 May 2021 ? ASLAN Pharmaceutica |
|
| April 23, 2021 |
Description Of Securities Registered Under Section 12 of the Exchange Act. Exhibit 2.4 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT As of December 31, 2020, ASLAN Pharmaceuticals Limited, or ?we,? ?us,? and ?our?, had the following series of securities registered pursuant to Section 12(b) of the Securities Exchange Act, as amended, or Exchange Act: Title of each class Trading symbol Name of each exchange on which registered American Depositar |
|
| April 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| April 23, 2021 |
EX-15.2 9 asln-ex1521162.htm EX-15.2 Exhibit 15.2 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement No. 333-252118 on Form S-8 of our report dated April 16, 2020, relating to the consolidated financial statements of ASLAN Pharmaceuticals Limited appearing in this Annual Report on Form 20-F for the year ended December 31, |
|
| April 23, 2021 |
Consent of Independent Registered Public Accounting Firm, Deloitte & Touche LLP EX-15.1 8 asln-ex1511163.htm EX-15.1 Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement No. 333-252118 on Form S-8 of our report dated April 22, 2021, relating to the consolidated financial statements of ASLAN Pharmaceuticals Limited appearing in this Annual Report on Form 20-F for the year ended December 31, |
|
| April 23, 2021 |
Exhibit 12.2 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Kiran Asarpota, certify that: 1) I have reviewed this annual report on Form 20-F of ASLAN Pharmaceuticals Limited (the ?Company?); 2) Based on my knowledge, this report does not contain any untrue statement of a mate |
|
| April 23, 2021 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), Carl Firth, Ph.D., Chief Executive Officer of ASLAN Pharmaceuticals Limited (the ?Company?), hereby certifies that, to the |
|
| April 23, 2021 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), Kiran Asarpota, Vice President of Finance of ASLAN Pharmaceuticals Limited (the ?Company?), hereby certifies that, to the b |
|
| April 23, 2021 |
Exhibit 12.1 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Carl Firth, certify that: 1) I have reviewed this annual report on Form 20-F of ASLAN Pharmaceuticals Limited (the ?Company?); 2) Based on my knowledge, this report does not contain any untrue statement of a material |
|
| April 22, 2021 |
Exhibit 99.1 PRESS RELEASE ASLAN PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE ? Next data readout for ASLAN004 in the treatment of patients with moderate to severe atopic dermatitis anticipated in the third quarter of 2021 Singapore, 22 April 2021 ? ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutica |
|
| April 22, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 April 22, 2021 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant?s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organisation) 83 CLEMENCEAU A |
|
| March 31, 2021 |
ASLAN Pharmaceuticals Limited 83 Clemenceau Avenue #12-03 UE Square Singapore 239920 March 31, 2021 VIA EDGAR U. |
|
| March 26, 2021 |
As filed with the Securities and Exchange Commission on March 26, 2021 Registration No. |
|
| March 18, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 March 18, 2021 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant?s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organisation) 83 CLEMENCEAU A |
|
| March 4, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 March 4, 2021 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant?s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organisation) 83 CLEMENCEAU AV |
|
| March 4, 2021 |
ASLAN PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES Exhibit 99.2 PRESS RELEASE ASLAN PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES Singapore, 2 March 2021 ? ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the pricing of an underwritten public offering of 15,000,000 American Dep |
|
| March 4, 2021 |
15,000,000 American Depositary Shares Representing 75,000,000 Ordinary Shares 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-252575 PRELIMINARY PROSPECTUS SUPPLEMENT (To Prospectus Dated February 11, 2021) 15,000,000 American Depositary Shares Representing 75,000,000 Ordinary Shares We are offering 15,000,000 American Depositary Shares, or ADSs. Each ADS represents five ordinary shares and will be evidenced by American Depositary Receipts, or |
|
| March 4, 2021 |
ASLAN PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES EX-99.1 Exhibit 99.1 PRESS RELEASE ASLAN PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES Singapore, 1 March 2021 – ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has commenced an underwritten public offering of $60.0 mill |
|
| March 4, 2021 |
EX-1.1 2 d15126dex11.htm EX-1.1 Exhibit 1.1 15,000,000 American Depositary Shares Representing 75,000,000 Ordinary Shares (Nominal Value $0.01 Per Share) ASLAN Pharmaceuticals Limited UNDERWRITING AGREEMENT March 2, 2021 JEFFERIES LLC PIPER SANDLER & CO. As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o PIPER SANDLER & CO. U.S. Bancorp |
|
| March 1, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 March 1, 2021 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant?s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organization) 83 CLEMENCEAU AV |
|
| March 1, 2021 |
EX-99.2 3 d143780dex992.htm EX-99.2 Exhibit 99.2 RISK FACTORS An investment in our American Depositary Shares, or ADSs, involves a high degree of risk. You should carefully consider the following risk factors, together with the information contained in our Annual Report on Form 20-F for the year ended December 31, 2019 filed with the Securities and Exchange Commission, or the SEC, on April 16, 202 |
|
| March 1, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 March 1, 2021 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant?s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organization) 83 CLEMENCEAU AV |
|
| March 1, 2021 |
Subject to Completion, dated March 1, 2021 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-252575 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has become effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these s |
|
| March 1, 2021 |
EX-99.1 Exhibit 99.1 Company Overview We are a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. Our portfolio is led by ASLAN004, a potential first-in-class human monoclonal antibody that binds to the IL-13 receptor α1 subunit (IL-13Rα1), blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13 which are ce |
|
| February 25, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 February 25, 2021 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant?s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organization) 83 CLEMENCEA |
|
| February 25, 2021 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of February 24, 2021 (the ?Effective Date?), among ASLAN Pharmaceuticals Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands (the ?Company?), and each purchaser identified on Exhibit A attached hereto (each a ?Purchaser? and collectively the |
|
| February 18, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 February 18, 2021 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant?s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organisation) 83 CLEMENCEA |
|
| February 11, 2021 |
SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1 )* ASLAN Pharmaceuticals Limited (Name of Issuer) Ordinary shares, par value NT$10.00 per share (“Shares”) |
|
| February 9, 2021 |
ASLAN Pharmaceuticals Limited 83 Clemenceau Avenue #12-03 UE Square Singapore 239920 February 9, 2021 VIA EDGAR U. |
|
| February 9, 2021 |
F-3/A Table of Contents As filed with the Securities and Exchange Commission on February 9, 2021 Registration No. |
|
| February 4, 2021 |
Letter from Deloitte Taiwan dated February 3, 2021 EX-15.1 2 asln-ex15119.htm EX-15.1 Exhibit 15.1 February 3, 2021 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-7561 Dear Sirs/ Madams: We have read ASLAN Pharmaceuticals Limited's Form 6-K dated February 3, 2021, and we agree with the statements made therein. Yours truly, Deloitte & Touche Taipei, Taiwan Republic of China |
|
| February 4, 2021 |
Current Report of Foreign Issuer - 6-K 6-K 1 asln-6k20210203.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 February 3, 2021 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant’s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation |
|
| January 29, 2021 |
EX-99.1 2 d105069dex991.htm EX-99.1 Exhibit 99.1 ASLAN PHARMACEUTICALS LIMITED AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In U.S. Dollars) (Unaudited) December 31, 2019 September 30, 2020 Amount Amount ASSETS CURRENT ASSETS Cash and cash equivalents (Note 6) $ 22,203,031 $ 12,060,285 Other Receivables — 12,552 Prepayments 68,923 341,978 Total current assets 22,271,954 12,414,815 NON-C |
|
| January 29, 2021 |
Current Report of Foreign Issuer - FORM 6-K Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 January 29, 2021 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant’s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organization) 83 C |
|
| January 29, 2021 |
Form F-3 Table of Contents As filed with the Securities and Exchange Commission on January 29, 2021 Registration No. |
|
| January 15, 2021 |
S-8 As filed with the Securities and Exchange Commission on January 15, 2021 Registration No. |
|
| January 11, 2021 |
ASLAN PHARMACEUTICALS OPENS EXPANSION COHORT IN ASLAN004 ATOPIC DERMATITIS CLINICAL TRIAL EX-99.1 2 asln-ex99129.htm EX-99.1 Exhibit 99.1 PRESS RELEASE ASLAN PHARMACEUTICALS OPENS EXPANSION COHORT IN ASLAN004 ATOPIC DERMATITIS CLINICAL TRIAL - ASLAN has completed recruitment of patients into the third, highest dose cohort of ASLAN004 in AD patients. ASLAN004 was found to be well tolerated at all dose levels - Data Monitoring Committee approved proposal to open the expansion cohort base |
|
| January 11, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 January 11, 2021 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant’s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organization) 83 CLEMENCEAU |
|
| December 11, 2020 |
American Depositary Shares representing Ordinary Shares 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-234405 AMENDMENT NO. 1 DATED DECEMBER 11, 2020 To Prospectus Supplement Dated October 9, 2020 (To Prospectus Dated November 8, 2019) $50,000,000 American Depositary Shares representing Ordinary Shares This Amendment No. 1 to Prospectus Supplement, or this Amendment, amends our prospectus supplement dated October 9, 2020, or the Prospectus |
|
| December 11, 2020 |
Current Report of Foreign Issuer - FORM 6-K Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 December 11, 2020 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant’s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organization) 83 |
|
| December 10, 2020 |
ASLAN Pharmaceuticals Limited 2020 Equity Incentive Plan asln-ex418.htm Exhibit 4.1 ASLAN PHARMACEUTICALS LIMITED 2020 Equity Incentive Plan Adopted by the Board of Directors: December 10, 2020 7208835 v3 CONTENTS ClausePage 1. PURPOSE1 2. ELIGIBILITY1 3. ADMINISTRATION AND DELEGATION1 4. SHARES AVAILABLE FOR AWARDS.1 5. OPTIONS AND SHARE APPRECIATION RIGHTS.2 6. RESTRICTED SHARES; RESTRICTED SHARE UNITS; PERFORMANCE SHARE UNITS4 7. OTHER SHARE BASED AW |
|
| December 10, 2020 |
ASLAN Pharmaceuticals Limited 2020 Equity Incentive Plan. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 December 10, 2020 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant?s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organisation) 83 CLEMENCEA |
|
| November 13, 2020 |
Current Report of Foreign Issuer - 6-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 November 13, 2020 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant’s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organisation) 83 CLEMENC |
|
| November 13, 2020 |
Press release dated November 9, 2020 regarding 3Q20 financial release and corporate update. Exhibit 99.1 PRESS RELEASE ASLAN PHARMACEUTICALS REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE Singapore, 9 November 2020 – ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the third quarter ended September 30, 202 |
|
| November 9, 2020 |
ASLAN Pharmaceuticals Limited CONSOLIDATED BALANCE SHEET1 (in US dollars) Exhibit 99.1 PRESS RELEASE ASLAN PHARMACEUTICALS REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE Singapore, 9 November 2020 ? ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the third quarter ended September 30, 202 |
|
| November 9, 2020 |
November 9, 2020 (as amended by the Form 6-K/A filed on UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 November 9, 2020 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant?s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organisation) 83 CLEMENCEAU |
|
| October 9, 2020 |
EX-99.2 Exhibit 99.2 DESCRIPTION OF SHARE CAPITAL General We are an exempted company incorporated in June 2014 with limited liability under the laws of the Cayman Islands and our affairs are governed by: • Our Ninth Amended and Restated Memorandum and Articles of Association (Articles); • the Companies Law (as amended) of the Cayman Islands (Companies Law); and • the common law of the Cayman Islan |
|
| October 9, 2020 |
EX-99.1 Exhibit 99.1 ASLAN PHARMACEUTICALS LIMITED AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In U.S. Dollars) (Unaudited) December 31, 2019 June 30, 2020 Amount Amount ASSETS CURRENT ASSETS Cash and cash equivalents (Note 6) $ 22,203,031 $ 13,827,444 Prepayments 68,923 295,202 Total current assets 22,271,954 14,122,646 NON-CURRENT ASSETS Financial assets at fair value through profit |
|
| October 9, 2020 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 October 9, 2020 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant’s name into English) CAYMAN ISLANDS (Jurisdiction of incorporation or organization) 83 CL |
|
| October 9, 2020 |
EX-1.2 3 d21815dex12.htm EX-1.2 Exhibit 1.2 THE COMPANIES LAW (AS AMENDED) COMPANY LIMITED BY SHARES TENTH AMENDED AND RESTATED MEMORANDUM OF ASSOCIATION OF ASLAN PHARMACEUTICALS LIMITED (ADOPTED BY SPECIAL RESOLUTION PASSED ON 04 SEPTEMBER 2020) 1. The name of the company is ASLAN Pharmaceuticals Limited (the “Company”). 2. The registered office of the Company will be situated at the offices of W |
|
| October 9, 2020 |
EX-99.4 Exhibit 99.4 RISK FACTORS An investment in our American Depositary Shares (ADSs) involves a high degree of risk. You should carefully consider the following risk factors, together with the information contained in our Annual Report on Form 20-F for the year ended December 31, 2019 filed with the Securities and Exchange Commission on April 16, 2020, before deciding whether to invest in our |
|
| October 9, 2020 |
Ninth Amended and Restated Memorandum and Articles of Association of ASLAN Pharmaceuticals Limited. EX-1.1 Exhibit 1.1 THE COMPANIES LAW (AS AMENDED) COMPANY LIMITED BY SHARES NINTH AMENDED AND RESTATED MEMORANDUM OF ASSOCIATION OF ASLAN PHARMACEUTICALS LIMITED (ADOPTED BY SPECIAL RESOLUTION PASSED ON 04 SEPTEMBER 2020) 1. The name of the company is ASLAN Pharmaceuticals Limited (the “Company”). 2. The registered office of the Company will be situated at the offices of Walkers Corporate Limited |
|
| October 9, 2020 |
EX-99.5 Exhibit 99.5 OPEN MARKET SALE AGREEMENTSM October 9, 2020 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: ASLAN Pharmaceuticals Limited, an exempted company incorporated with limited liability in the Cayman Islands (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales |
|
| October 9, 2020 |
American Depositary Shares representing Ordinary Shares 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-234405 PROSPECTUS SUPPLEMENT (To Prospectus Dated November 8, 2019) $7,500,000 American Depositary Shares representing Ordinary Shares We have entered into a certain Open Market Sale AgreementSM, or Sales Agreement, with Jefferies LLC, or Jefferies, relating to American Depositary Shares, or ADSs, each representing five |
|
| October 9, 2020 |
DESCRIPTION OF AMERICAN DEPOSITARY SHARES EX-99.3 7 d21815dex993.htm EX-99.3 Exhibit 99.3 DESCRIPTION OF AMERICAN DEPOSITARY SHARES American Depositary Receipts JPMorgan Chase Bank, N.A. (JPMorgan) as depositary will issue the American Depositary Shares (ADSs) in connection with an offering. Each ADS will represent an ownership interest in a designated number of our ordinary shares which we will deposit with the depositary or the custodia |
|
| September 22, 2020 |
Exhibit 99.1 PRESS RELEASE ASLAN PHARMACEUTICALS COMPLETES ENROLMENT IN SECOND COHORT AND OPENS NEW SITES IN US AND AUSTRALIA IN ASLAN004 ATOPIC DERMATITIS STUDY Singapore, 21 September 2020 – ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that clini |
|
| September 22, 2020 |
6-K 1 asln-6k20200921.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 September 21, 2020 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant’s name into English) CAYMAN ISLANDS (Jurisdiction of incorporatio |
|
| September 17, 2020 |
6-K 1 asln-6k20200917.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 September 17, 2020 (Commission File No. 001-38475) ASLAN PHARMACEUTICALS LIMITED (REG. NO. 289175) (Translation of registrant’s name into English) CAYMAN ISLANDS (Jurisdiction of incorporatio |
